TNFRSF1A and neoplasm: We found that, compared to the vehicle-treated group, NF-κB inhibition was able to slightly extend the lifespan of mice which had received Tnfr−/− LCs, while a combination of JNK or NF-κB inhibitors also significantly reduced the tumor burden and prolonged the life of Tnfr−/− leukemic mice (Figure 1D–1F).